Mesalamine Dosing for Microscopic Colitis
Mesalamine is not recommended for microscopic colitis—budesonide 9 mg once daily is the first-line therapy for induction of remission. 1
Primary Treatment Recommendation
Budesonide 9 mg once daily for 8 weeks is the strongly recommended first-line therapy for symptomatic microscopic colitis, based on the 2016 AGA guideline. 1 This recommendation is supported by randomized controlled trials demonstrating superior efficacy over both mesalamine and placebo. 2, 3
Evidence Against Mesalamine in Microscopic Colitis
Mesalamine 3 g once daily showed no significant benefit over placebo in achieving clinical remission in lymphocytic colitis (63% vs 42%, P = 0.09). 2
In collagenous colitis, mesalamine 3 g once daily was ineffective, with only 44% achieving clinical remission compared to 80% with budesonide (P = 0.0035). 3
The AGA guideline explicitly recommends against combination therapy with cholestyramine and mesalamine over mesalamine alone, further underscoring mesalamine's limited role. 1
A 2024 meta-analysis confirmed budesonide's superiority, showing significantly higher clinical remission rates at 8 weeks (RR=2.29) compared to mesalamine (RR=1.7, P=0.003). 4
Budesonide Dosing Strategy
Induction Therapy
Budesonide 9 mg once daily for 8 weeks achieves clinical remission in approximately 80% of patients with microscopic colitis. 1, 2, 3
Clinical remission is defined as ≤3 stools per day (or ≤21 stools including ≤6 watery stools in 7 days). 2, 3
Budesonide also achieves histologic remission in 68% of patients, significantly higher than mesalamine (26%) or placebo (21%). 2
Maintenance Therapy
Maintenance therapy should only be offered to patients who relapse after cessation of induction therapy—up to one-third of patients may not require maintenance. 1
Budesonide 6 mg daily for 6 months reduces clinical relapse risk by 66% (RR 0.34,95% CI 0.19–0.6). 1
Lower-dose maintenance (3 mg alternating with 6 mg daily) over 12 months shows similar efficacy and should be considered to minimize steroid exposure. 1
Taper to the lowest effective dose in clinical practice, and consider cessation after 6–12 months of maintenance. 1
Monitor for bone loss with prolonged budesonide use and implement osteoporosis prevention/screening as needed. 1
Safety Profile
Budesonide is associated with significantly fewer adverse events than mesalamine (P=0.002 in meta-analysis). 4
The incidence of adverse events with budesonide 9 mg was 47.4%, comparable to placebo (42.1%), and lower than mesalamine (68.4%). 2
Serious adverse events are rare with budesonide, and the favorable safety profile supports its use as first-line therapy. 1, 3
Clinical Pitfalls to Avoid
Do not use mesalamine as first-line therapy for microscopic colitis—the evidence clearly demonstrates lack of efficacy compared to budesonide. 1, 2, 3
Do not initiate maintenance therapy immediately after induction—assess for relapse first, as many patients remain in remission without maintenance. 1
Do not overlook medication triggers—NSAIDs, proton pump inhibitors, and antidepressants are associated with microscopic colitis, though recent studies have challenged the strength of these associations. 5
Do not confuse microscopic colitis with ulcerative colitis—the dosing recommendations for mesalamine in UC (2.4–4.8 g/day) do not apply to microscopic colitis. 6
Alternative Therapies for Refractory Disease
For patients with budesonide-refractory microscopic colitis, consider immunosuppressants (azathioprine) or anti-TNF agents, though evidence is limited to case series. 1
Antidiarrheal agents (loperamide) and cholestyramine monotherapy may be considered for mild symptoms, though rigorous clinical trial data are lacking. 1, 5
Bismuth subsalicylate is another option for mild disease, particularly when budesonide is not tolerated or contraindicated. 5